PLYMOUTH MEETING, PA — INOVIO said existing cash reserves are expected to fund operations into the first quarter of 2027, extending beyond a key FDA decision on its lead therapy as the biotechnology company attempts to secure its first commercial product approval.
The company’s outlook is increasingly tied to the outcome of the U.S. Food and Drug Administration’s review of INO-3107, an experimental treatment for recurrent respiratory papillomatosis, or RRP, with a target Prescription Drug User Fee Act date of October 30, 2026.
The FDA previously identified a potential issue regarding whether the therapy qualifies for review under the accelerated approval pathway, creating additional regulatory uncertainty around INOVIO’s primary commercialization effort.
The company disclosed that the agency recently completed a mid-cycle review meeting and plans further discussions regarding accelerated-approval eligibility.
“We remain focused on advancing INO-3107 toward its target PDUFA date,” Chief Executive Officer Jacqueline Shea said, adding that the company believes the therapy could reduce the need for repeated surgeries among RRP patients if approved.
INOVIO is simultaneously advancing launch preparations ahead of a possible 2026 approval, including agreements involving specialty distribution, pharmacy support, logistics, patient services, and a contract sales organization.
The company reported $37.7 million in cash, cash equivalents, and short-term investments as of March 31, excluding approximately $16 million raised through an April public equity offering.
INOVIO estimated second-quarter operational cash burn at roughly $18 million and stated current liquidity is expected to support operations beyond the FDA’s target review date, though projections exclude additional future financing activity.
The company reported a first-quarter net loss of $19.7 million, unchanged from the same period a year earlier, while operating expenses declined to $21.9 million from $25.1 million.
Research and development expenses fell to $14.1 million from $16.1 million, while general and administrative expenses declined to $7.9 million from $9 million.
INO-3107 is being developed for RRP, a rare HPV-linked disease that can require patients to undergo repeated surgical removal of tumors in the respiratory tract.
INOVIO also continues expanding its oncology pipeline through a clinical trial collaboration with Akeso involving INO-5412 and cadonilimab for glioblastoma treatment in a Phase 2 study sponsored by the Dana-Farber Cancer Institute.
The partnership adds to a highly competitive glioblastoma treatment landscape where experimental immunotherapies have historically struggled to demonstrate durable late-stage efficacy.
INOVIO also highlighted earlier-stage DNA medicine programs targeting Hemophilia A, Fabry disease, and hypophosphatasia as the company continues pursuing external partnerships and additional capital sources.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.